The Women's Health Initiative randomized trials & clinical practice
JAMA 2024 review synthesizes 20+ years of WHI follow-up.
OVUM Editorial·
Executive summary
JAMA 2024 review synthesizes 20+ years of WHI follow-up. In the timing-hypothesis window (<10 yrs from menopause or <60), MHT shows no significant rise in all-cause mortality and a possible benefit for estrogen-alone in younger women. OVUM files this under prevention and biomarkers in women's health.
Key findings
- In the timing-hypothesis window (<10 yrs from menopause or <60), MHT shows no significant rise in all-cause mortality and a possible benefit for estrogen-alone in younger women.
Market implications
- Most aging biomarkers were validated in mixed or male populations, so women-specific reference ranges are still being established.
- A preventive product needs sex-specific evidence before an employer or payer will fund it.
- Measurement alone is widely available. What distinguishes a product is the intervention it triggers.
Professional access
Interpretative layer
Professional access includes investor relevance, OVUM view, and category-level implications.
Source and methodology
Compiled from the published article, its classification, and OVUM's internal taxonomy. Last indexed Jun 12, 2026.
Article summary
In the timing-hypothesis window (<10 yrs from menopause or <60), MHT shows no significant rise in all-cause mortality and a possible benefit for estrogen-alone in younger women.
HRTWHIMortality